<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.4-a.1'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//yakulens.jp/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://yakulens.jp/2026/10/13/zongertinib-120mg-eligibility-diarrhea-dose-hold/</loc>
  <lastmod>2026-10-13T09:16:08Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>ヤクレンズ</news:name>
    <news:language>ja</news:language>
   </news:publication>
   <news:title>ゾンゲルチニブ：120mg処方と休薬判断の要点</news:title>
   <news:publication_date>2026-10-13T09:16:08Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://yakulens.jp/2026/10/13/imlunestrant-esr1-post-progression-fasting-interactions/</loc>
  <lastmod>2026-10-13T09:15:35Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>ヤクレンズ</news:name>
    <news:language>ja</news:language>
   </news:publication>
   <news:title>イムルネストラント（イムルリオ）導入前の確認点：ESR1検査・空腹時投与・併用薬をつなぐ</news:title>
   <news:publication_date>2026-10-13T09:15:35Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
